20,840 Shares in Oruka Therapeutics, Inc. $ORKA Purchased by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management purchased 20,840 Oruka Therapeutics shares in the second quarter, valued at approximately $1.98 million. Institutional investors and hedge funds collectively own 56.44% of the company.
• Analyst sentiment remains broadly positive, with 10 Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $134.30. However, insiders sold 83,116 shares worth about $6.64 million over the past 90 days.
• Oruka shares opened at $101.82, near their 52-week high of $115.51, while the company reported a quarterly loss of $0.55 per share—$0.04 worse than analysts expected. Its lead oncology candidate, ONCT-01, is in Phase 1 trials.

ADAR1 Capital Management LLC bought a new stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,840 shares of the company's stock, valued at approximately $1,983,000.

Other institutional investors also recently bought and sold shares of the company. Legal & General Group Plc purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its position in shares of Oruka Therapeutics by 464.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after purchasing an additional 2,306 shares during the last quarter. Royal Bank of Canada grew its stake in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the fourth quarter worth $37,000. Finally, PNC Financial Services Group Inc. purchased a new position in Oruka Therapeutics in the third quarter valued at $39,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ORKA. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research report on Thursday, April 30th. Weiss Ratings raised Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 15th. HC Wainwright restated a "buy" rating and set a $120.00 target price on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Wall Street Zen downgraded Oruka Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Finally, BTIG Research reiterated a "buy" rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $134.30.

Insiders Place Their Bets

In related news, SVP Arjun Agarwal sold 10,000 shares of the firm's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00. Following the completion of the transaction, the senior vice president directly owned 15,312 shares of the company's stock, valued at $1,633,177.92. This trade represents a 39.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $111.84, for a total value of $782,880.00. Following the completion of the transaction, the insider directly owned 32,718 shares of the company's stock, valued at $3,659,181.12. The trade was a 17.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,116 shares of company stock worth $6,636,533 in the last ninety days. 23.49% of the stock is owned by insiders.

Oruka Therapeutics Stock Down 0.6%

NASDAQ ORKA opened at $101.82 on Wednesday. Oruka Therapeutics, Inc. has a 52-week low of $14.34 and a 52-week high of $115.51. The business's 50-day moving average price is $93.17 and its 200 day moving average price is $66.41. The firm has a market cap of $6.74 billion, a P/E ratio of -50.16 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, analysts anticipate that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

Want to see what other hedge funds are holding ORKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source